Cash Flow Statement
Growth Metrics

Anika Therapeutics (ANIK) Cash from Investing Activities (2016 - 2025)

Anika Therapeutics (ANIK) has disclosed Cash from Investing Activities for 16 consecutive years, with $198000.0 as the latest value for Q4 2025.

  • Quarterly Cash from Investing Activities rose 115.15% to $198000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$401000.0 through Dec 2025, up 95.19% year-over-year, with the annual reading at -$401000.0 for FY2025, 95.19% up from the prior year.
  • Cash from Investing Activities for Q4 2025 was $198000.0 at Anika Therapeutics, up from -$1.7 million in the prior quarter.
  • The five-year high for Cash from Investing Activities was $1.7 million in Q1 2021, with the low at -$3.4 million in Q2 2024.
  • Average Cash from Investing Activities over 5 years is -$1.2 million, with a median of -$1.4 million recorded in 2023.
  • The sharpest move saw Cash from Investing Activities tumbled 176.47% in 2022, then skyrocketed 192.48% in 2025.
  • Over 5 years, Cash from Investing Activities stood at -$1.2 million in 2021, then plummeted by 103.95% to -$2.5 million in 2022, then grew by 27.24% to -$1.8 million in 2023, then rose by 28.97% to -$1.3 million in 2024, then soared by 115.15% to $198000.0 in 2025.
  • According to Business Quant data, Cash from Investing Activities over the past three periods came in at $198000.0, -$1.7 million, and -$539000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.